Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Lung InfectionPneumonia, Ventilator-AssociatedInfection, BacterialStaphylococcus Aureus
Interventions
DRUG

AR-301

AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.

OTHER

Placebo

Placebo comparator

Trial Locations (45)

1340

BEL-05, Ottignies

1400

GEO-06, Gori

2193

ZAF-09, Johannesburg

4600

GEO-01, Kutaisi

GEO-03, Kutaisi

GEO-04, Kutaisi

GEO-10, Kutaisi

6042

BEL-01, Lodelinsart

13419

EST-01, Tallinn

19312

FRA-18, Brive-la-Gaillarde

28040

ESP-01, Madrid

31096

ISR-04, Haifa

34214

TUR-06, Istanbul

35033

FRA-11, Rennes

44093

FRA-01, Nantes

44280

MEX-07, Guadalajara

45067

FRA-16, Orléans

58000

UKR-05, Chernivtsi

61080

TUR-01, Trabzon

61103

UKR-02, Kharkiv

UKR-09, Kharkiv

67091

FRA-02, Strasbourg

69677

FRA-10, Bron

76008

UKR-03, Ivano-Frankivsk

85925

FRA-05, La Roche-sur-Yon

87042

FRA-04, Limoges

90400

FRA-13, Trévenans

140180

RUS-16, Zhukovskiy

163002

RUS-18, Arkhangelsk

192242

RUS-02, Saint Petersburg

214018

RUS-10, Smolensk

223041

BLR-01, Minsk

230017

BLR-06, Grodno

246029

BLR-04, Homyel

454000

RUS-11, Chelyabinsk

510180

CHN-09, Guangzhou

630051

RUS-04, Novosibirsk

660022

RUS-01, Krasnoyarsk

5262100

ISR-01, Ramat Gan

80810-050

BRA-08, Curitiba

82050-350

BRA-04, Curitiba

0141

GEO-02, Tbilisi

0159

GEO-09, Tbilisi

0160

GEO-07, Tbilisi

LV-1006

LVA-02, Riga

Sponsors
All Listed Sponsors
lead

Aridis Pharmaceuticals, Inc.

INDUSTRY